Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: About 20% of patients (pts) with neuroendocrine tumors (NET) suffer from carcinoid syndrome (CS), mainly from ileum and lung NET. Pts with CS experience symptoms such as diarrhea, flushes and cardiac complications. The diarrhea occurs in almost all pts with CS and can be truly debilitating. Therefore, on top of the tumor, the burden of the symptoms further impairs quality of life and is associated with additional costs related to symptom management and pts follow-up.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Walter T
Authors: Walter T, Lapeyre Mestre M, Gueguen D, Bouille C, Laborey M,
Keywords: Carcinoid syndrome, resources, health economics,
Introduction: Lanreotide autogel (LAN) and octreotide LAR (OCT) are long acting somatostatin analogues (LA-SSAs) used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previous studies conducted in North America and Sweden showed some differences between both LA-SSAs in terms of dose and persistence.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Fagnani F, Feuilly M, Marteau F, de Zélicourt M, Kamenicky P,
Keywords: somatostatin analogues, treatment patterns, resource use,
Introduction: The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of pancreatic adenocarcinoma is better in patients with blood group O. This has not been extensively explored in PanNET.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: De Rycke O, Védie A, Guarneri G, Nin F, De Flori C,
Keywords: blood group, pancreatic NET, prognosis, recurrence,
Introduction: A new syringe (NS) for the delivery of lanreotide autogel was approved in Oct 2018 in France. The NS includes updated features (larger flanges, more robust plunger) intended to ease the injection.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Walter T, Eskenazi M, Rama N, Gueguen D, Mir O,
Keywords: neuroendocrine tumors, lanreotide, nursing, patient-reported outcomes,
Introduction: A new formulation of octreotide LAR (OCT LAR) with a new diluent has been developed to facilitate the preparation and administration.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Coriat R
Authors: Cadiot G, Coriat R, Raverot G, Nguyen Tan Hon T, Raingeard I,
Keywords: Octreotide LAR, NET, Acromegaly, Nurse,